Doug Spicer Email & Phone Number

Seattle, Wa, Us

Houston, Texas, Us

 Decommissioning of laboratory and asset management for sales  Laboratory Manager oversaw equipment computer updates, repairs, and preventative maintenance Recover of PBMC’s of clinical patient samples and banking of the samples for screening of elite responders Basic use of flowcytometry to assess the viability of recovered PBMC’s prior to storage Review & update existing automation platforms’ OS for BCC screening initiative Analyzed & recommend replacements for deficiencies in automation hardware for BCC screening initiative  Proposed multiplexed antibody/protein targeted screen using Meso Scale Discovery platform; proprietary chemiluminescent system  Interfaced with service providers for maintenance of equipment and infrastructure Advised & Supervised Research Associate projects Assisted executive administers for purchasing, & inventory of capital assets

Seattle, Washington, Us

SPE for high abundance proteins for Biomarker StudiesAutomation Optimization of plasma depletion for high throughput, large scale human octogenarian study Optimization of tryptic digestion of depleted plasma for high throughput, large scale octogenarian human study Automation initiative for the high throughput, large scale human octogenarian study  Analysis of depleted plasma samples using the Thermo Scientific Eclipse / Lumos DIA methods comparing quality and reproducibility of tryptic digested and depleted plasma using the Trans Proteomic Pipeline (TPP), a suite of analysis software created, curated, maintained and available from ISB Familiar with Skyline, R and Xcalibur software

Louisville, Colorado, Us

 Acquisition/Transition integral member of the transition team for the Nodify™ lung cancer risk assessment assay (formally branded as XpressysTM Biomarker Assay  Product Development; conversion of the Biomarker Plasma Depletion assay to an affinity capture assay for TOF mass spectrometry Product Improvement increase of throughput of biomarker assay using a whole blood separation device cutting cost of sample shipping, storage, and processing Automation Initiative; conversion of the affinity capture assay to a high through put automated assay projected through put a 10 fold increase of daily sample processing Scheduled PM for equipment to ensure no downtime for clinical assay Forecast equipment usage and redundancy of equipment to ensure no downtime for clinical assay Scheduled training and managed several research associates for R & D projects for product improvement and development Post company acquisition retained for technology transfer prior to facility relocation

 Formulated IQ, OQ and PQ processes for new Mass Spectrometry Procurement Developed SOPs for all laboratory processes of CLIA and CAP regulated environ General Supervisor for CAP / CLIA regulated laboratory environ Maintain Mass Spectrometry Instrumentation for Biomarker Panel Assay Participated multiple study designs for validation of key reagents and standards Spear heading automation initiative for increased production throughput  Developed OQ of automation to be used in the CAP / CLIA XpressysTM Biomarker Assay Maintenance of the LC-MS systems for CLIA and CAP regulated environ Brought on for method and tech transfer of assay process Assumed responsibility for Mass Spectrometry Instrumentation  Developed process improvements for tech transfer of assay Evaluated Mass Spectrometry Chromatography of selected Biomarker panel Participated in Assay Validation Study of tech transfer including assessment of SRM/MRM triggered biomarker panel Trained new employees for Validated Assay

Seattle, Washington, Us

We worked in the Rob Moritz Laboratory at the ISB using Automation to prepare samples for Mass Spectrometric analysis. We also curated and prepared samples for the soon to be published MRM Atlas, a compendium of synthetic in-silico tryptic peptides of the Swiss Prot database consisting of over 160,000 peptides. We personally contributed over 25,000 spectra from the Agilent Triple Quad 6460 to the Atlas.

30+ employees, biotech startup, focus is both infectious disease and cancer human monoclonal therapeutics. Recovery of antibodies is from B cell activation cultures. Among my duties outside of Lab manager I currently head the cell screeniing efforts on the In Cell 1000, from GE.

McLaughlin Research Institute is an independent, non-profit research organization in Great Falls, Montana near the Rocky Mountain Front. Research at the institute focuses on understanding the genetic control of normal development and disease susceptibility using the mouse as a model system. The institute fosters a collegial, interactive environment, minimizing bureaucratic impediments to research.My position entailed planning, implementing a breeding program of geneticly relavent mouse models for the study of prion disease in order to help elucidate the quantitative trait loci position for the prion disease susceptability. Also included in my tasks as the iintercranial nnoculation of mice with prions and procurement of brain tissue for mRNA array studies.

Wheatley, Oxfordshire, Gb

Privately held company manufacturing Biotechnology discovery tools using the propriatary synthetic affinity pair of PDBA and SHA. The platform included protein microarrays, fully automated dye terminator removal kits and a biosensor application.

Research International emphasizes hardware implementation of all research and development efforts and thus maintains an on-site machine shop, plus well-equipped microfabrication and chemistry/biochemistry laboratories. The manufacturing department, containing electronics, optics, and mechanical assembly areas, is designed for small to medium production runs. Research International excels at rapidly converting proof-of-principle bench technology to pre-production and production instrumentation.My position included developing biological assays for the Raptor, functionalizing the polystyrene wave guides for protien moditfication, testing a novel laser diode pH meter for a culture system and QC instruments from the production line.

Fee for service laboratory. Provided DNA sequencing and genotyping.

Privately held company formed to discover the genetic causes of aging. Two main thrusts, a genetic study of octigenarian sibling pairs and a basic research comparing the genetic differences between Rodents and Budgies. Developed the standardized approach for high through-put RT-DD-PCR (Reverse Transcriptase Differential Display- Polymerase Chain Reaction) and SSCP (Single Strand Confrimation Polymorphism).

Seattle, Wa, Us

Dr. CK Abrass' laboratory in collaboration with Dr. G Raugi worked on the causes of diabetic nephropathy in long term IDDM (Insulin Dependant Diabeties Mellitus.) I developed a novel messangial cell line that was responsive to pharmalogical doses of insulin which assisted in elucidating the sclerotic mechanism found in IDDM patients.